Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. - Wikidata - awgldk - TriplyDB

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

http://www.wikidata.org/entity/Q40715894

about

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy.Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Therapeutic options in neuromyelitis optica spectrum disorders.Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.Natalizumab in relapsing-remitting multiple sclerosis.What's new in neuromyelitis optica? A short review for the clinical neurologist.Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.Optic Nerve.Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience.Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial.Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder.Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis

P2860

Q26748601-717C986A-ED5D-483B-8446-6F7D84045115 Q33562130-CCF914B1-1CA1-4382-BE77-742508F64357 Q33909097-714B0290-E224-4DDF-A4DF-A8B2D7D83BB3 Q36359371-D5862D80-AACC-41FE-9860-0B7A21E08AE5 Q37045814-4A8C249A-0B17-4234-BC10-2DC64092A74B Q37620483-5006B963-521F-4A7C-9BC7-125593409E48 Q38721559-D1B5019C-86C5-4C00-AAE9-457528B4F410 Q38750021-C9CE4F0C-192E-4994-BE3E-EF9662E7FAF4 Q38786252-6ECA94AC-0C30-4E16-8447-325409470FE8 Q39176987-89A797AA-9187-454F-ACCA-2DB23242113F Q39692977-21652FA7-0A3D-44C1-9B7C-67566F6195A0 Q40481942-C999FC84-4964-4EA3-A504-C544766C6AA2 Q41626170-BF0AC22F-6CAE-4D2A-A173-1C2D306EFCA5 Q48198452-B60D9A20-9DB3-4FDE-8F5C-FD840BE73E15 Q53125112-5A984D7E-508E-4BB3-9782-B0CBE3FEC4FF Q54982151-8C4139C8-95AB-418B-8F9A-EE9DC300328A Q55068903-FDBFC8A4-0C26-4CA8-ADDF-8DB89F582B39 Q58573155-5D745F96-CC5F-45D2-AD3D-007F91877260

P2860

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

http://www.wikidata.org/entity/Q40715894

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

@en

type

label

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

@en

prefLabel

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

@en

P1433

Q40715894-507E7D81-E8BE-4026-BC0B-7DE24E5AC455

P1476

Q40715894-A901DB1C-0C02-4A1F-A88E-15D43A6BFFBF

P2093

Q40715894-0072302E-5047-4F81-BA84-D197F7A7E50A

Q40715894-0BF2A1D0-B95D-405B-BBA9-65BEBFBD1836

Q40715894-4C45E00F-E0AB-4DBC-962E-8086BC9878F7

Q40715894-B447646A-DE54-4278-A573-98212133BF50

Q40715894-CB50EC44-CAA9-4825-9DD7-7561CDE9285E

Q40715894-DBDAD8E8-6611-49FC-AB6A-AE81098DF5CC

Q40715894-E1EA5583-1D9F-4402-9A84-A9258CA28C39

Q40715894-E23E733C-1BA3-4F8A-A5E9-BE288BB7D132

P2860

Q40715894-0524E2E5-123B-4736-ABA8-52F77906BAC0

Q40715894-0C21504F-D1E2-486F-A5BD-29740279136D

Q40715894-48083BC0-3611-41F0-B428-E51F837E3A5F

Q40715894-5BB71B67-3D1D-4B8C-872E-7428E87AEEAA

Q40715894-6E48625A-9EC6-4917-A60E-0C1579004A14

Q40715894-740529F4-2DC7-4090-862F-D7E30C1D23EB

Q40715894-8533A31F-FA8F-4EF5-A052-800D954B91AD

Q40715894-8541D67A-58EB-4D9C-BD9C-C0492158C979

Q40715894-8D3AF26D-E32E-4730-A07A-C78929AD643E

Q40715894-93BC96A6-2374-4704-AFE5-EE4CA673367C

P2888

Q40715894-81A016F5-453E-49F3-AB62-7C83A134A116

P304

Q40715894-F5A275D5-6F73-4EB5-AAC1-88C7F0E8AEC5

P31

Q40715894-0555DC3D-B593-4142-A82C-40F8D3EFA42A

P356

Q40715894-A45BDEE9-D7CD-4DCC-839D-0C4131A2C14E

P433

Q40715894-BBA57717-F379-4821-B2A4-7FBF6614C4A4

P478

Q40715894-63F5B0EA-EC85-4CA4-A5A9-4969C59D09D3

P50

Q40715894-3D836CB2-E1EA-4A2E-A786-555DA28F5683

Q40715894-692A1056-83E7-4D72-8A2B-CABF018E134D

Q40715894-9BC3F8DD-62ED-4748-830F-B1492E299148

Q40715894-AA5DD589-3E7D-40FF-BF93-2EA7DD1F2110

Q40715894-B8BDDD7C-F341-420E-B9BD-1F32E32FE275

Q40715894-DC02AF96-96EC-43CC-9546-1615B004B6E5

P577

Q40715894-FA078E02-88E7-4E3D-963A-3865EF041F54

P698

Q40715894-6FEF94E8-508C-4AE1-A096-D8F1F0B8BBCF

P356

S00415-015-7852-Y

P1433

Journal of Neurology

P1476

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

@en

P2093

Bertrand Audoin

http://www.w3.org/2001/XMLSchema#string

Bertrand Bourre

http://www.w3.org/2001/XMLSchema#string

Christine Lebrun

http://www.w3.org/2001/XMLSchema#string

David Brassat

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Neau

http://www.w3.org/2001/XMLSchema#string

Romain Marignier

http://www.w3.org/2001/XMLSchema#string

Sandrine Wiertlewski

http://www.w3.org/2001/XMLSchema#string

Sophie Pittion

http://www.w3.org/2001/XMLSchema#string

P2860

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Revised diagnostic criteria for neuromyelitis optica.

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica

Treatment of Neuromyelitis Optica: Review and Recommendations.

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.

B cells in MS and NMO: pathogenesis and therapy.

P2888

s00415-015-7852-y

P304

2329-2335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-015-7852-Y

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

262

http://www.w3.org/2001/XMLSchema#string

P50

Raphaël Bernard-Valnet

Jean-Christophe Ouallet

Olivier Outteryck

P577

2015-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26194198

http://www.w3.org/2001/XMLSchema#string